retatrutide phase 2 results obesity nejm 2023 Among participants 4 to 66 years of age with acquired hypothalamic obesity, setmelanotide, a melanocortin-4 receptor agonist, led to significantly greater reductions in body-mass index and hunger than placebo at 52 weeks 🚨 BREAKING: Retatrutide Shows “Bariatric-Level”

SURMOUNT-1 (NEJM 2022) showed 22.5% mean weight loss at 72 weeks on the 15 mg dose

Given retatrutide's potency, extremely conservative dosing would be warranted: Start with minimum doses of both compounds Extend escalation intervals to 6-8 weeks per step Monitor for enhanced metabolic effects and potential hypoglycemia Adjust based on individual metabolic response For those researching advanced peptide protocols, these combination approaches illustrate the complexity and potential of multi-pathway interventions

Understanding the regulatory landscape helps contextualize why products like CrazyLeaf exist in a legal grey zone

The ultimate decision will come from continued and future trial results

All products referenced are intended strictly for laboratory research use

Interleukin-1, interleukin-6, epidermal growth factor and transforming growth factor- are elevated in the brain from Parkinsonian patients